Orsini G, Laricchia L, Fanelli M
III Unità Operativa di Ginecologia e Ostetricia, Cattedra di Fisiopatologia della Riproduzione Umana, Dipartimento di Scienze Chirurgiche, Università degli Studi, Bari, Italy.
Minerva Ginecol. 2002 Jun;54(3):253-61.
To evaluate the effects of the last generation of oral contraceptives (OC) on uterine leiomyomas.
non-randomized perspective study on the effects of the last generation of oral contraceptives on uterine myomas during 24 months follow-up.
III Unit of Obstetrics and Gynecology, University of Bari.
between 1999 and 2000 a total of 121 asymptomatic women with only one subserous and/or intramural uterine myoma, having diameter pound 25 mm have been recruited. These patients were divided into two groups: the treatment group was composed of 53 women and was treated with last generation pill containing 20 microgram of ethynilestradiol and 150 microgram of desogestrel or 20 microgram of ethynilestradiol and 75 microgram of gestodene, while the control group was composed of 68 women having no hormonal therapy. In both groups the uterine myoma size (evaluated by transvaginal ultrasonography), the duration of menstrual flow and the hematocrit at the time of recruitment, after 12 months and after 24 months were examined.
Forty-eight (90.6%) women belonging to the study group completed 2 years of OC use; only sixty women (88.2%) belonging to the control group completed the study. The use of the last generation oral contraceptives for 2 years didn't increase significantly uterine myomas size; besides after 24 months there was a significant reduction of more than two days of menstrual flow, and a significant increase of two and a half points of hematocrit. On the contrary, in the control group, we found a significant increase of uterine myoma volume, a not significant increase of menses duration and a not significant reduction of hematocrit.
The prolonged use of the last generation of oral contraceptives does not affect the uterine myomas volume increase and furthermore it produces a significant reduction in the duration of menstrual flow with a significant increase in hematocrit.
评估上一代口服避孕药（OC）对子宫平滑肌瘤的影响。
对上一代口服避孕药在24个月随访期间对子宫肌瘤影响的非随机前瞻性研究。
巴里大学妇产科第三单元。
在1999年至2000年期间，共招募了121名无症状女性，她们仅有一个浆膜下和/或肌壁间子宫肌瘤，直径≤25mm。这些患者被分为两组：治疗组由53名女性组成，接受含有20微克乙炔雌二醇和150微克去氧孕烯或20微克乙炔雌二醇和75微克孕二烯酮的上一代避孕药治疗，而对照组由68名未接受激素治疗的女性组成。在两组中，均检查了子宫肌瘤大小（通过经阴道超声检查评估）、月经持续时间以及招募时、12个月后和24个月后的血细胞比容。
研究组中有48名（90.6%）女性完成了2年的口服避孕药使用；对照组中只有60名（88.2%）女性完成了研究。使用上一代口服避孕药2年并未显著增加子宫肌瘤大小；此外，24个月后月经流量显著减少超过两天，血细胞比容显著增加两个半百分点。相反，在对照组中，我们发现子宫肌瘤体积显著增加，月经持续时间无显著增加，血细胞比容无显著降低。
长期使用上一代口服避孕药不会影响子宫肌瘤体积的增加，而且会使月经流量持续时间显著缩短，血细胞比容显著增加。
